EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Key Points Interested in Candel Therapeutics, Inc.? Here are five stocks we like better. Candel Therapeutics said it remains ...

Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates ...

Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 9:00 AM EDTCompany ParticipantsAndrew Peters - Senior ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...